SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.Curtin, M.L., Pliushchev, M.A., Li, H.Q., Torrent, M., Dietrich, J.D., Jakob, C.G., Zhu, H., Zhao, H., Wang, Y., Ji, Z., Clark, R.F., Sarris, K.A., Selvaraju, S., Shaw, B., Algire, M.A., He, Y., Richardson, P.L., Sweis, R.F., Sun, C., Chiang, G.G., Michaelides, M.R.
(2017) Bioorg Med Chem Lett 27: 1576-1583
- PubMed: 28254486
- DOI: https://doi.org/10.1016/j.bmcl.2017.02.030
- Primary Citation of Related Structures:
5U69, 5U6D, 5U8A, 5U8F
- PubMed Abstract:
Herein we disclose SAR studies of a series of dimethylamino pyrrolidines which we recently reported as novel inhibitors of the PRC2 complex through disruption of EED/H3K27me3 binding. Modification of the indole and benzyl moieties of screening hit 1 provided analogs with substantially improved binding and cellular activities. This work culminated in the identification of compound 2, our nanomolar proof-of-concept (PoC) inhibitor which provided on-target tumor growth inhibition in a mouse xenograft model. X-ray crystal structures of several inhibitors bound in the EED active-site are also discussed.
AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States.